US006811794B2

(12) **United States Patent**
Burnside et al.

(10) **Patent No.: US 6,811,794 B2**
(45) **Date of Patent: Nov. 2, 2004**

(54) **SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORMS WITH MINIMIZED PH DEPENDENT DISSOLUTION PROFILES**

(75) Inventors: **Beth A. Burnside**, Bethesda, MD (US); **Rong-Kun Chang**, Rockville, MD (US); **Xiaodi Guo**, New City, NY (US)

(73) Assignee: **Shire Laboratories, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 196 days.

(21) Appl. No.: **10/027,349**

(22) Filed: **Dec. 20, 2001**

(65) **Prior Publication Data**

US 2003/0158261 A1 Aug. 21, 2003

(51) **Int. Cl.**[7] **A61K 9/22**
(52) **U.S. Cl.** **424/468**
(58) **Field of Search** 424/468

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,968,508	A	11/1990	Oren et al.	424/468
5,102,668	A	4/1992	Eichel et al.	424/490
5,378,474	A	1/1995	Morella et al.	424/469
6,287,599	B1 *	9/2001	Burnside et al.	424/468
2004/0064800	A1 *	4/2004	Korobkov	716/10

* cited by examiner

Primary Examiner—Alton Pryor
(74) *Attorney, Agent, or Firm*—M. Elisa Lane

(57) **ABSTRACT**

A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.

12 Claims, 2 Drawing Sheets